| NPS PHARMACEUTICALS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120003681 | EX VIVO METHOD FOR DETERMINING POTENTIAL GLP-2 RECEPTOR MODULATIONS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-05-2012 |
| 20110172152 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 07-14-2011 |
| 20110130556 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2(1-34) PEPTIDES - The invention provides methods for making peptides from a polypeptide containing at least one copy of the peptide using clostripain to excise the peptide from the polypeptide. The methods enable the use of a single, highly efficient enzymatic cleavage to produce any desired peptide sequence. | 06-02-2011 |
| 20110092424 | PRODUCTION OF GLUCAGON LIKE PEPTIDE 2 AND ANALOGS - GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In a specific embodiment, [Gly | 04-21-2011 |
| 20110071081 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 03-24-2011 |
| 20110009320 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 01-13-2011 |
| 20100068732 | CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. | 03-18-2010 |
| 20100003703 | ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue. | 01-07-2010 |
| 20090275578 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators - The present invention is directed to compounds of formula I: | 11-05-2009 |
| 20090176993 | Calcium receptor active compounds - A novel calcium receptor active compound having the formula is provided: | 07-09-2009 |
